AGAP2 and glioma: A large quantity of studies have testified to the aberrant expression of AGAP2-AS1 in human malignancies, including glioma, colorectal, lung, ovarian, prostate, breast, cholangiocarcinoma, bladder, colon and pancreatic cancers.